Key result
A two-dose inactivated hepatitis A vaccine induced long-term immune persistence, with 100% and 97.3% of subjects remaining seropositive at 15 years for the 0,6 and 0,12 month schedules, respectively.
Why the study?
Does a two-dose inactivated hepatitis A vaccine provide long-term antibody persistence at 15 years in healthy adults?
Does a two-dose inactivated hepatitis A vaccine provide long-term antibody persistence at 15 years in healthy adults?
A two-dose inactivated hepatitis A vaccine induces an immune response that persists for at least 15 years in healthy adults, regardless of whether the second dose is given at 6 or 12 months.
Answers are grounded in this paper and cite their sources.
15-year anti-HAV persistence observed; extends observational durability data but leaves open booster recommendations.
Long-term persistence of vaccine-induced immune response in adults was assessed annually for 15 years following primary immunization with a two-dose inactivated hepatitis A vaccine. In 1992, 119 and 194 subjects aged 17-40 years and naïve for hepatitis A virus (HAV) were enrolled in two studies to receive 1,440 ELISA units (El.U) of inactivated hepatitis A vaccine (Havrix™, GlaxoSmithKline Biologicals, Belgium) according to a standard 0, 6 or an extended 0, 12 months schedule, respectively. Serum samples were taken 1 month after the second vaccine dose and every consecutive year up to 15 years after primary vaccination for measurement of anti-HAV antibody concentrations (NCT00291876 and NCT00289757). At year 15, 100% (48/48) and 97.3% (108/111) of subjects vaccinated at 0, 6 or 0, 12 months remained seropositive for anti-HAV antibodies, with geometric mean concentrations (GMCs) of 289.2 and 367.4 mIU/ml, respectively. An additional dose of HAV vaccine (1,440 El.U) was administered to the six subjects who had become seronegative for anti-HAV antibodies since year 11. All subjects mounted a humoral immune response to the additional HAV challenge dose, although post-challenge anti-HAV antibody levels remained low in one subject. These studies represent the longest annual follow-up of hepatitis A vaccine in healthy adults. The immune response induced by two doses of this inactivated HAV vaccine was shown to persist for at least 15 years. No difference in long-term antibody persistence was observed between the two primary vaccination schedules, reinforcing the potential for flexibility in the timing of the second primary vaccine dose.
No takes yet. Share an insight, caveat, or question.
Herck et al. (2011) studied Healthy adults naïve for hepatitis A virus (n=313). Inactivated hepatitis A vaccine (Havrix) vs. 1,440 ELISA units (El.U) at 0, 12 months was evaluated on Seropositivity for anti-HAV antibodies at 15 years. A two-dose inactivated hepatitis A vaccine induced long-term immune persistence, with 100% and 97.3% of subjects remaining seropositive at 15 years for the 0,6 and 0,12 month schedules, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: